Specialty Pharmacy

Genetic information may help develop treatment guidelines for Crohn's disease and ulcerative colitis.

Patients with diabetes fare better after surgery when pharmacists manage their high blood sugar.

Micro RNA based blood test may be used with imaging features to accurately predict disease severity.

Once-a-week treatment is the first oral proteasome inhibitor to reach late stage clinical development.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses the alignment between specialty pharmacies and ACOs.

Benefits of Plavix found to outweigh potential adverse events.

Rectal microbicide formulated as an enema may inhibit the spread of HIV and other sexually transmitted infections.

Combination of sofosbuvir and simeprevir may have an unexpected side effect in HCV therapy.

Roflumilast has been found to help prevent flare-ups associated with COPD.

HIV-1-associated neurocognitive disorders afflict almost half of all patients with HIV.

The Institute for Safe Medication Practices (ISMP) is alerting pharmacists about the risks of mixing up idarucizumab (Praxbind) with idarubicin.

Serum levels may determine impact of anti-tumor necrosis factor drugs.

Recent news in cancer drug development.

Lawsuits challenge access denials to curative hepatitis C drugs among incarcerated individuals infected with the disease.

Study may lead to vaccines that force an immune response.

Little or no genetic association found in disease behavior.

Researchers seek to determine which side effects will be experienced by different patient groups.

Top stories of the week on Specialty Pharmacy Times.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses how the ACA has impacted the specialty landscape.

Some patients with MS received a benefit from natalizumab involving the reduction of relapses and new MRI lesions.

Prescription drug use increased significantly among persons aged 40 to 64 years and among those age 65 and older.

People living in poorer areas less likely to receive screening.

The US Senate has launched a bipartisan investigation into prescription drug pricing, targeting Valeant, Turing Pharma, Retrophin, and Rodelis in particular.

Gilead's Genvoya is the first TAF-based regimen approved by the FDA.

Terms like revolutionary or miracle cause confusion for readers.

Biofilm proteins show promise in treatment of gastrointestinal disorders.

Nucala is for use with other asthma drugs for the maintenance of patients 12 years and older.

Liver disease experts suggest how to prioritize the treatment of different HCV patient groups.